Penumbra (PEN) vs 10x Genomics (TXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
10x Genomics (TXG) has outperformed Penumbra (PEN) over the past year, gaining 556.0% versus a gain of 27.0%. Over five years, PEN leads with a +18.2% price change compared with -50.0% for TXG. Penumbra is the larger company by market cap ($12.46 billion vs $9.92 billion), about 1.3 times the size.
On valuation, Penumbra trades at a lower forward P/E (51.6x vs 992.6x for 10x Genomics). Penumbra converts more of its revenue into profit, with a net margin of 12.7% versus -6.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PEN | TXG |
|---|---|---|
| Share price | $316.35 | $76.10 |
| Market cap | $12.46B | $9.92B |
| 1-day change | -0.22% | -5.65% |
| YTD return | +1.75% | +366.58% |
| 1-year return | +27.03% | +556.03% |
| 5-year return | +18.15% | -50.02% |
| P/E ratio (TTM) | 77.73 | — |
| Forward P/E | 51.59 | 992.57 |
| EPS (TTM) | $4.07 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.40B | $642.82M |
| Revenue growth (YoY) | +17.50% | +5.25% |
| Net income (latest FY) | $177.69M | $-43.54M |
| Gross margin | 67.14% | 69.05% |
| Operating margin | 13.48% | -9.49% |
| Net margin | 12.66% | -6.77% |
| 52-week high | $362.41 | $102.81 |
| 52-week low | $221.26 | $11.16 |
| Distance from 52-week high | -12.71% | -25.98% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +14.30% | -13.27% |
| Average volume | 344.71K | 3.25M |
| Shares outstanding | 39.39M | 120.21M |
| Employees | 4,700 | 1,178 |
| Sector | Health Care | Industrials |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TXG has outperformed PEN by 529.0 percentage points over the past year.
- Penumbra is more profitable, keeping 12.7 cents of every revenue dollar as net income versus -6.8 cents for 10x Genomics.
- Penumbra grew revenue faster in its latest fiscal year (+17.50% vs +5.25%).
- The two companies sit in different sectors: Penumbra in Health Care and 10x Genomics in Industrials.
About Penumbra
PEN stock →Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Health Care · Medical/Dental Instruments · 4,700 employees
About 10x Genomics
TXG stock →10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Industrials · Biotechnology: Laboratory Analytical Instruments · 1,178 employees
PEN vs TXG FAQ
Which is bigger, Penumbra or 10x Genomics?
Penumbra (PEN) is larger, with a market capitalization of $12.46B compared with $9.92B for 10x Genomics (TXG).
Which stock has performed better over the past year, PEN or TXG?
TXG returned +556.03% over the past 12 months, compared with +27.03% for PEN (price return, excluding dividends). Past performance does not predict future results.
Are Penumbra and 10x Genomics in the same industry?
No. Penumbra is in the Health Care sector, while 10x Genomics is in Industrials.